How does Counterclaim generate an insurance appeal letter?

Counterclaim uses a 5-agent AI pipeline. The Reader extracts claim data from your document. The Researcher identifies applicable state insurance law. The Writer drafts a formal appeal letter. The Adversary identifies weaknesses. The Editor rewrites the letter to eliminate all weaknesses. The final letter is ready to print and mail in minutes.

Is Counterclaim free to use?

Yes - Counterclaim is free during the launch period. Upload your denial letter and receive a complete adversary-tested appeal letter at no cost. No account required.

What types of insurance denials can Counterclaim handle?

Counterclaim handles all major denial types: medical necessity (CO-50), prior authorization (CO-11), experimental treatment (PR-1), fee schedule (CO-45), timely filing (PR-27), not covered (CO-4), step therapy (PR-50), and missing information (CO-16).

What file formats does Counterclaim accept?

Counterclaim accepts PDF files, JPG and PNG photos, and scanned documents of your denial letter or Explanation of Benefits (EOB).

Does Counterclaim provide legal advice?

No. Counterclaim generates appeal letters based on publicly available legal and clinical information but does not constitute legal advice. For complex cases, consult a licensed healthcare attorney or certified patient advocate.

What is step therapy and how do I get an exception?

Step therapy requires patients to try a lower-cost drug before the plan will cover a more expensive one. State step-therapy reform laws (in over 30 states) require expedited exception processes when the required step is medically inappropriate, has been tried and failed, is contraindicated, or expected to cause harm. File the exception with documented evidence of prior trial, contraindication, or expected harm.

Why was my Humira denied in favor of a biosimilar?

Many plans have moved branded Humira to non-preferred status during 2023-2024 and require an adalimumab biosimilar first (Hyrimoz, Yusimry, Cyltezo, Hadlima, others). The appeal angle is documented intolerance to the alternative, history of antidrug antibodies, or stable disease control on Humira where switching presents documented risk.

Can I appeal a Medicare Part D coverage determination?

Yes. Part D coverage determinations and exception requests are governed by 42 CFR Part 423 Subpart M. The appeal path is plan redetermination, then IRE reconsideration (administered by Maximus), then ALJ, then Medicare Appeals Council, then federal court. Strict timeframes apply - request standard or expedited review depending on clinical urgency.

What is a formulary exception?

A formulary exception is a request for the plan to cover a drug not on its formulary, or to cover a non-preferred drug at the preferred cost-sharing tier. The standard requires medical evidence that formulary alternatives would be ineffective, would cause adverse effects, or are otherwise inappropriate.

Can my plan force me to use its captive specialty pharmacy?

Generally yes - specialty pharmacy network restrictions are enforceable in most plan contracts and require the drug to be filled through the PBM-owned specialty pharmacy (CVS Specialty, Accredo, OptumRx Specialty). Limited exceptions exist for specific drugs that another pharmacy is uniquely positioned to dispense or where access is genuinely inadequate.

What clinical guidelines should I cite in a specialty drug appeal?

Cite the most authoritative guideline for your condition: NCCN for oncology, ACR for rheumatology, AAD for dermatology, AAN for neurology, IDSA for infectious disease, ACG/AGA for gastroenterology. For off-label indications, citation of DrugDex, AHFS, or NCCN Drugs and Biologics Compendium is particularly persuasive because Medicare and many commercial plans formally recognize these compendia.

Specialty Rx

Specialty Medications (Tier 4-5) Insurance Denial Appeal — Free AI Letter

Specialty medication denied, step therapy required, or prior auth refused? Generate a free appeal letter in minutes - including state step-therapy law citations.

Why specialty medications (tier 4-5) denials happen so often

Specialty medications are high-cost, often biologic or complex small-molecule drugs that treat chronic, complex, or rare conditions. They typically require special handling, specialty pharmacy distribution, prior authorization, and frequently sit on Tier 4 or Tier 5 of the formulary with the highest patient cost-sharing. Examples include biologics for autoimmune disease (Humira/adalimumab, Enbrel/etanercept, Stelara/ustekinumab, Skyrizi/risankizumab), MS therapies (Ocrevus, Tysabri, Tecfidera), oncology oral drugs (Imbruvica, Tagrisso, Revlimid), HIV pre-exposure prophylaxis, hepatitis C antivirals, and cystic fibrosis modulators (Trikafta). Pharmacy benefit managers (PBMs) and the plans they serve apply prior authorization, step therapy, quantity limits, and increasingly aggressive 'preferred biosimilar' or 'preferred biologic' substitution rules. The denials are appealable, especially under state step-therapy reform laws and exception-process requirements.

Why Specialty Rx gets denied

Step therapy required - patient must fail a lower-cost alternative first

Prior authorization not approved - clinical criteria not met or documentation incomplete

Off-label use not on the plan's approved indication list

Quantity limit exceeded for the requested fill

Formulary exclusion - drug not on the formulary at all

Non-preferred status - drug requires higher cost-sharing or pre-step

Specialty pharmacy network restriction - drug must be filled at a specific PBM-owned specialty pharmacy

Coverage gap during formulary change at plan year boundary

Federal and state protections for Specialty Rx

Specialty drug coverage is governed by your plan's pharmacy benefit contract and, for ACA-regulated plans, by the formulary requirements at 45 CFR section 156.122. Internal appeal and external review rights apply under 45 CFR section 147.136. State step-therapy reform laws now in effect in more than 30 states (e.g. New York Public Health Law section 4910, California Health and Safety Code section 1367.244, Colorado Revised Statutes section 10-16-145) require expedited exception processes when step therapy is medically inappropriate, the required step has been tried, is contraindicated, or is expected to cause harm. Medicare Part D coverage determinations and exceptions are governed by 42 CFR Part 423 Subpart M; the appeal path runs through plan redetermination, IRE reconsideration, ALJ, MAC, and federal court. ERISA self-funded plans must provide full and fair review under 29 CFR section 2560.503-1.

Evidence checklist for your appeal

Letter of medical necessity from the prescribing specialist citing clinical guidelines (NCCN for oncology, ACR for rheumatology, AAD for dermatology, etc.)
Documentation of step therapy failures - specific drugs tried, dosage, duration, reason for failure or intolerance, dated medical records
Plan formulary and coverage policy with the relevant criteria identified
Compendium support for off-label indications - DrugDex, AHFS Drug Information, NCCN Drugs and Biologics Compendium (these are recognized by Medicare and most commercial plans for off-label cancer and other indications)
If state step-therapy law applies: citation of the state statute and explicit request for the expedited exception process
Manufacturer prescribing information and FDA-approved labeling
If formulary exclusion: comparison to comparable on-formulary drugs and documentation of why those alternatives are inappropriate

Common products

Humira (adalimumab) and biosimilars (Hyrimoz, Yusimry, Cyltezo, Hadlima)
Enbrel (etanercept)
Stelara (ustekinumab) and biosimilars (Wezlana)
Skyrizi (risankizumab)
Cosentyx (secukinumab)
Dupixent (dupilumab)
Ocrevus (ocrelizumab)
Trikafta (elexacaftor/tezacaftor/ivacaftor)
Imbruvica (ibrutinib), Tagrisso (osimertinib), Revlimid (lenalidomide)

Insurer-specific patterns and tactics

The big three PBMs - CVS Caremark (Aetna), Express Scripts/Evernorth (Cigna), and OptumRx (UnitedHealthcare) - each operate captive specialty pharmacies (CVS Specialty, Accredo, BriovaRx/OptumRx Specialty). Many specialty drug network restrictions require the drug to be filled at the captive pharmacy. Each PBM also publishes its own utilization management criteria and preferred drug lists, updated quarterly. The 2023-2024 trend has been aggressive interchange to biosimilars - many plans moved Humira to non-preferred and require Hyrimoz, Adalimumab-adbm, or another biosimilar first. State enforcement of step-therapy reform has been increasing; FTC scrutiny of PBM practices (2024 Interim Staff Report) has made appeals citing PBM market conduct more receptive.

Generate your Specialty Rx appeal letter

Upload your denial notice or EOB. Our 5-agent AI pipeline drafts a professional appeal that cites the specific statute, clinical policy, and evidence pattern relevant to a specialty rx denial - in about 2 minutes, free.

Upload my denial · Free

Frequently asked questions: Specialty Rx appeals

Appeal a Durable Medical Equipment (DME) denial

Appeal a Physical Therapy denial

Appeal a Occupational Therapy denial

Appeal a Speech Therapy denial

Appeal a Home Health Care denial

Appeal a Skilled Nursing Facility (SNF) denial

Related insurer guides

UnitedHealthcare appeals

Cigna appeals

Aetna appeals

Anthem appeals

Related denial codes

CO-50

Medical Necessity Denial (CO-50)

CO-11

Prior Authorization Denial (CO-11)